Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DOSTARLIMAB vs DOXEPIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DOSTARLIMAB vs DOXEPIN: Safety Overview

Metric DOSTARLIMAB DOXEPIN
Total FAERS Reports 893 4,021
Deaths Reported 130 1,613
Death Rate 14.6% 40.1%
Hospitalizations 441 1,091
Average Patient Age 65.8 yrs 49.2 yrs
% Female Patients 91.6% 63.8%
FDA Approval Date N/A Approved Prior to Jan 1, 1982
Manufacturer GlaxoSmithKline LLC Teva Pharmaceuticals USA, Inc.
Route INTRAVENOUS TOPICAL
Marketing Status N/A Discontinued